An Emollient Plus Balm Is Useful for the Management of Xerosis in Cancer Patients: A Real-World, Prospective, Observational, Multicenter Study

    February 2022 in “ Dermatology and therapy ”
    V. Vendrely, Ander Mayor-Ibarguren, Aline Stennevin, Ariadna Ortiz‐Brugués
    Studysummary This study found that daily use of an emollient PLUS containing ADE-G1 significantly reduced xerosis severity and improved quality of life in cancer patients, regardless of their initial xerosis severity or cancer treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Prophylaxis and Management of Skin Toxicities Breast care · 2019
    2. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails American Journal of Clinical Dermatology · 2018
    3. Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology Clinical & Translational Oncology · 2018